Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDPH.L Regulatory News (DPH)

  • There is currently no data for DPH

Form 8.3 - DECHRA PHARMACEUTICALS PLC

15 Dec 2023 12:09

RNS Number : 0173X
Barclays PLC
15 December 2023
Β 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR

MORE

Rule 8.3 of the Takeover Code (the "Code")

1.

KEY INFORMATION

(a)

Full name of discloser:

Β 

Barclays PLC.

(b)

Owner or controller of interest and short

Β 

Β 

positions disclosed, if different from 1(a):

(c)

Name of offeror/offeree in relation to whose

DECHRA PHARMACEUTICALS PLC

Β 

relevant securities this form relates:

(d)

If an exempt fund manager connected with an

Β 

Β 

offeror/offeree, state this and specify identity of

Β 

offeror/offeree:

(e)

Date position held/dealing undertaken:

14 Dec 2023

(f)

In addition to the company in 1(c) above, is the discloser making

NO

Β 

Β 

Β 

disclosures in respect of any other party to the offer?

Β 

Β 

2.

POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a)

Interests and short positions in the relevant securities of the offeror or offeree

Β 

Β 

to which the disclosure relates following the dealing(if any)

Β 

Class of relevant security:

1p ordinary

Β 

Interests

Short Positions

Β 

Number

(%)

Number

(%)

(1)

Relevant securities owned

Β 

Β 

Β 

Β 

Β 

and/or controlled:

Β 

Β 

7,537,068

6.62%

2,364,336

2.08%

(2)

Cash-settled derivatives:

Β 

Β 

Β 

Β 

Β 

and/or controlled:

Β 

Β 

950,636

0.83%

7,476,891

6.56%

(3)

Stock-settled derivatives (including options)

Β 

Β 

Β 

Β 

Β 

and agreements to purchase/sell:

Β 

Β 

0

0.00%

0

0.00%

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

TOTAL:

Β 

Β 

8,487,704

7.45%

9,841,227

8.64%

(b)

Rights to subscribe for new securities (including directors and other executive

Β 

Β 

options)

Β 

Β 

Β 

Β 

Β 

Β 

Class of relevant security in relation to

Β 

Β 

Β 

Β 

which subscription right exists

Β 

Β 

Β 

Β 

Details, including nature of the rights

Β 

Β 

Β 

Β 

concerned and relevant percentages:

Β 

Β 

Β 

Β 

3.

DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

(a)

Purchases and sales

Β 

Β 

Β 

Β 

Β 

Class of relevant

Purchase/sale

Number of

Price per unit

security

Β 

securities

Β 

1p ordinary

Purchase

45,163

38.4504 GBP

1p ordinary

Purchase

16,233

38.4600 GBP

1p ordinary

Purchase

9,547

38.4445 GBP

1p ordinary

Purchase

8,841

38.4319 GBP

1p ordinary

Purchase

5,067

38.4338 GBP

1p ordinary

Purchase

4,195

38.4580 GBP

1p ordinary

Purchase

2,193

38.4559 GBP

1p ordinary

Purchase

808

38.4495 GBP

1p ordinary

Purchase

515

38.3819 GBP

1p ordinary

Purchase

513

38.4000 GBP

1p ordinary

Purchase

440

38.4352 GBP

1p ordinary

Purchase

415

38.4238 GBP

1p ordinary

Purchase

402

38.4259 GBP

1p ordinary

Purchase

352

38.4800 GBP

1p ordinary

Purchase

220

38.4300 GBP

1p ordinary

Purchase

216

38.4403 GBP

1p ordinary

Purchase

188

38.4200 GBP

1p ordinary

Purchase

2

38.4400 GBP

1p ordinary

Sale

1,411,034

38.4600 GBP

1p ordinary

Sale

24,946

38.4400 GBP

1p ordinary

Sale

13,730

38.4317 GBP

1p ordinary

Sale

4,465

38.4593 GBP

1p ordinary

Sale

4,386

38.4591 GBP

1p ordinary

Sale

1,855

38.4156 GBP

1p ordinary

Sale

838

38.4123 GBP

1p ordinary

Sale

495

38.4119 GBP

1p ordinary

Sale

312

38.4098 GBP

1p ordinary

Sale

161

38.4200 GBP

1p ordinary

Sale

100

38.3800 GBP

1p ordinary

Sale

65

38.3600 GBP

1p ordinary

Sale

10

38.4360 GBP

1p ordinary

Sale

2

38.4561 GBP

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

(b)

Cash-settled derivative transactions

Β 

Class of

Product

Nature of dealing

Number of

Price per

relevant

description

Β 

reference

unit

security

Β 

Β 

securities

Β 

1p ordinary

SWAP

Decreasing Long

1,714

38.4282 GBP

1p ordinary

SWAP

Decreasing Long

9,023

38.4600 GBP

1p ordinary

SWAP

Decreasing Long

10,246

38.4452 GBP

1p ordinary

SWAP

Decreasing Short

3

38.4566 GBP

1p ordinary

SWAP

Decreasing Short

6

38.4161 GBP

1p ordinary

SWAP

Decreasing Short

7

38.4561 GBP

1p ordinary

SWAP

Decreasing Short

312

38.4098 GBP

1p ordinary

SWAP

Decreasing Short

838

38.4123 GBP

1p ordinary

CFD

Decreasing Short

1,045

38.4600 GBP

1p ordinary

SWAP

Decreasing Short

2,341

38.3969 GBP

1p ordinary

CFD

Decreasing Short

2,359

38.4148 GBP

1p ordinary

SWAP

Decreasing Short

3,340

38.4523 GBP

1p ordinary

SWAP

Decreasing Short

4,386

38.4591 GBP

1p ordinary

SWAP

Decreasing Short

8,085

38.4303 GBP

1p ordinary

SWAP

Decreasing Short

24,946

38.4400 GBP

1p ordinary

SWAP

Increasing Long

55

38.4200 GBP

1p ordinary

SWAP

Increasing Short

3

38.4300 GBP

1p ordinary

CFD

Increasing Short

29

38.4600 GBP

1p ordinary

SWAP

Increasing Short

415

38.4238 GBP

1p ordinary

SWAP

Increasing Short

1,072

38.4342 GBP

1p ordinary

SWAP

Increasing Short

3,293

38.4055 GBP

1p ordinary

SWAP

Increasing Short

8,322

38.4681 GBP

1p ordinary

SWAP

Increasing Short

8,841

38.4319 GBP

1p ordinary

SWAP

Increasing Short

15,209

38.4308 GBP

1p ordinary

SWAP

Increasing Short

27,827

38.4600 GBP

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

(c)

Stock-settled derivative transactions (including options)

Β 

(i)

Writing, selling, purchasing or varying

Β 

Class

Product

Writing,

Number

Exercise

Type

Expiry

Option

of

description

purchasing,

of

price

Β 

date

money

relevant

Β 

selling,

securities

per unit

Β 

Β 

paid/

security

Β 

varying etc

to which

Β 

Β 

Β 

received

Β 

Β 

Β 

option

Β 

Β 

Β 

per unit

Β 

Β 

Β 

relates

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

(ii)

Exercising

Β 

Β 

Β 

Β 

Β 

Β 

Class of relevant

Product description

Exercising/ exercised against

Number of

Exercise price per

security

Β 

Β 

securities

unit

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

(d)

Other dealings (including subscribing for new securities)

Β 

Class of relevant

Nature of Dealings

Details

Price per unit (if

security

Β 

Β 

applicable)

Β 

Β 

Β 

Β 

4.

OTHER INFORMATION

(a)

Indemnity and other dealings arrangements

Β 

Details of any indemnity or option arrangement, or any agreement or understanding,

Β 

Β 

formal or informal, relating to relevant securities which may be an inducement to deal

Β 

Β 

or refrain from dealing entered into by the exempt principal trader making the disclosure and any party

Β 

to the offer or any person acting in concert with a party to the offer:

Β 

Β 

Β 

NONE

(b)

Agreements, arrangements or understandings relating to options or derivatives

Β 

Details of any agreement, arrangement or understanding, formal or informal, between

Β 

Β 

the person making the disclosure and any other person relating to:

Β 

Β 

(i) the voting rights of any relevant securities under any option; or

Β 

Β 

Β 

(ii) the voting rights of future acquisition or disposal of any relevant securities to which

Β 

Β 

any derivative is referenced:

Β 

Β 

Β 

Β 

Β 

Β 

NONE

(c)

Attachments

Β 

Β 

Β 

Β 

Β 

Β 

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

15 Dec 2023

Contact name:

Large Holdings Regulatory Operations

Telephone number:

020 3134 7213

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
RETEAAASFENDFFA
Date   Source Headline
3rd Nov 20239:18 amRNSForm 8.3 - Dechra Pharmaceuticals plc
3rd Nov 20239:17 amRNSForm 8.3 - Dechra Pharmaceuticals plc
3rd Nov 20238:49 amRNSForm 8.5 (EPT/NON-RI) Dechra Pharmaceuticals Plc
3rd Nov 20237:34 amGNWForm 8.5 (EPT/RI) - Dechra Pharmaceuticals plc
3rd Nov 20237:05 amRNSForm 8.3 - Dechra Pharmaceuticals plc
2nd Nov 20234:52 pmRNSHolding(s) in Company
2nd Nov 20233:25 pmRNSForm 8.3 - Dechra Pharmaceuticals Plc
2nd Nov 20233:20 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
2nd Nov 20232:12 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
2nd Nov 20231:07 pmEQSForm 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
2nd Nov 202312:57 pmGNWForm 8.3 - Dechra Pharmaceuticals Plc
2nd Nov 202312:40 pmPRNForm 8.3 - Dechra Pharmaceuticals Plc
2nd Nov 202311:59 amRNSForm 8.5 (EPT/RI)-Replacement of Dechra
2nd Nov 202311:54 amPRNForm 8.3 - Dechra Pharmaceuticals PLC
2nd Nov 202311:35 amRNSForm 8.3 - Dechra Pharmaceuticals plc
2nd Nov 202311:24 amRNSForm 8.3 - DECHRA PHARMACEUTICALS PLC
2nd Nov 202311:14 amRNSForm 8.5 (EPT/NON-RI)
2nd Nov 202311:13 amRNSForm 8.5 (EPT/RI)
2nd Nov 202310:53 amRNSHolding(s) in Company
2nd Nov 20239:36 amRNSForm 8.5 (EPT/RI)- Dechra Pharmaceuticals plc
2nd Nov 20239:30 amRNSForm 8.3 - Dechra Pharmaceuticals plc
2nd Nov 20239:16 amRNSForm 8.3 - Dechra Pharmaceuticals plc
2nd Nov 20238:50 amRNSForm 8.3 - DECHRA PHARMACEUTICALS PLC Amend
2nd Nov 20238:49 amRNSForm 8.3 - DECHRA PHARMACEUTICALS PLC Amend
2nd Nov 20238:48 amRNSForm 8.3 - DECHRA PHARMACEUTICALS PLC Amend
2nd Nov 20238:18 amRNSForm 8.5 (EPT/NON-RI) Dechra Pharmaceuticals Plc
1st Nov 20233:37 pmRNSHolding(s) in Company
1st Nov 20233:20 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
1st Nov 20233:10 pmRNSHolding(s) in Company
1st Nov 20232:46 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
1st Nov 20232:41 pmRNSHolding(s) in Company
1st Nov 20231:22 pmPRNForm 8.3 - Dechra Pharmaceuticals Plc
1st Nov 20231:01 pmEQSForm 8.3 - The Vanguard Group, Inc.: Dechra Pharmaceuticals plc
1st Nov 202312:38 pmRNSForm 8.3 - DECHRA PHARMACEUTICALS PLC
1st Nov 202312:30 pmPRNForm 8.3 - Dechra Pharmaceuticals PLC
1st Nov 202312:10 pmRNSForm 8.5 (EPT/RI)-Replacement of Dechra
1st Nov 202311:51 amRNSForm 8.5 (EPT/RI)
1st Nov 202311:49 amRNSForm 8.5 (EPT/NON-RI)
1st Nov 202311:30 amGNWForm 8.3 - Dechra Pharmaceuticals Plc
1st Nov 202311:20 amRNSForm 8.3 - Dechra Pharmaceuticals plc
1st Nov 202310:00 amRNSUpdate on Financing Arrangements
1st Nov 20239:48 amRNSForm 8.3 - Dechra Pharmaceuticals plc
1st Nov 20239:21 amRNSForm 8.5 (EPT/NON-RI) Dechra Pharmaceuticals Plc
1st Nov 20239:02 amRNSForm 8.5 (EPT/RI)- Dechra Pharmaceuticals plc
31st Oct 20233:36 pmGNWForm 8.3 - Dechra Pharmaceuticals plc
31st Oct 20233:25 pmBUSForm 8.3 - Dechra Pharmaceuticals plc
31st Oct 20233:20 pmRNSForm 8.3 - Dechra Pharmaceuticals plc
31st Oct 20233:02 pmRNSHolding(s) in Company
31st Oct 20233:00 pmBUSForm 8.3 - DPH LN
31st Oct 20232:48 pmBUSForm 8.3 - Dechra Pharmaceuticals plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.